Dose-Specific Packaging for Lenvatinib in Endometrial Cancer Could Improve Adherence, But Drives Overspending

In an interview with Pharmacy Times, Emeline Aviki, MD, discussed research presented at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer regarding dose-specific packaging in lenvatinib.

In part 1 of the discussion, Aviki said lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy. Dose-specific packaging is often used with lenvatinib because it is believed to improve adherence, but Aviki said that it can also lead to overspending when patients are prescribed dose-reductions before finishing the 30-day prescription.